Cantor Fitzgerald Predicts Zai Lab FY2026 Earnings

Zai Lab Limited (NASDAQ:ZLAB) – Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Zai Lab in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings per share of $1.38 for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share.

Zai Lab (NASDAQ:ZLAB) last issued its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.05. The firm had revenue of $106.49 million during the quarter, compared to analysts’ expectations of $118.40 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%.

ZLAB has been the subject of a number of other reports. JPMorgan Chase & Co. raised their target price on shares of Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, March 13th. Bank of America reaffirmed a “neutral” rating and issued a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. Finally, Scotiabank started coverage on shares of Zai Lab in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 price objective for the company.

Zai Lab Stock Performance

Shares of NASDAQ:ZLAB opened at $41.40 on Wednesday. The stock has a market capitalization of $4.57 billion, a price-to-earnings ratio of -14.95 and a beta of 0.96. Zai Lab has a 1-year low of $16.01 and a 1-year high of $41.44. The company has a 50 day moving average price of $31.22 and a 200 day moving average price of $30.31.

Institutional Investors Weigh In On Zai Lab

Institutional investors and hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. acquired a new stake in shares of Zai Lab in the 4th quarter valued at $46,172,000. Raymond James Financial Inc. acquired a new stake in shares of Zai Lab in the 4th quarter valued at $1,032,000. Alberta Investment Management Corp lifted its stake in shares of Zai Lab by 42.9% in the 4th quarter. Alberta Investment Management Corp now owns 232,293 shares of the company’s stock valued at $6,084,000 after purchasing an additional 69,740 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Zai Lab by 1,439.8% in the 4th quarter. BNP Paribas Financial Markets now owns 19,755 shares of the company’s stock valued at $517,000 after purchasing an additional 18,472 shares during the last quarter. Finally, FMR LLC lifted its stake in shares of Zai Lab by 749.1% in the 4th quarter. FMR LLC now owns 5,475,505 shares of the company’s stock valued at $143,403,000 after purchasing an additional 4,830,646 shares during the last quarter. Institutional investors and hedge funds own 41.65% of the company’s stock.

Insider Buying and Selling

In other Zai Lab news, insider Frazor Titus Edmondson III sold 4,369 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $35.89, for a total value of $156,803.41. Following the completion of the sale, the insider now owns 27,217 shares in the company, valued at $976,818.13. This represents a 13.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rafael Amado sold 3,000 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $38.41, for a total transaction of $115,230.00. Following the completion of the sale, the insider now owns 30,834 shares of the company’s stock, valued at approximately $1,184,333.94. The trade was a 8.87% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 130,207 shares of company stock valued at $3,880,239. Company insiders own 4.96% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.